[{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Selective-5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Anagnostou, Evdokia, M.D.","sponsor":"Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU ","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"Anagnostou, Evdokia, M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anagnostou, Evdokia, M.D. \/ Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU ","highestDevelopmentStatusID":"8","companyTruncated":"Anagnostou, Evdokia, M.D. \/ Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU "},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"National Institute of Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ National Institute of Mental Health","highestDevelopmentStatusID":"11","companyTruncated":"Alto Neuroscience \/ National Institute of Mental Health"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Aremis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 28, 2010

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 28, 2010

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Rexulti (brexpiprazole) 5-HT2A receptor, is being evaluated in combination with sertraline in late-stage clinical trials with adult patients for the treatment of post-traumatic stress disorder.

                          Product Name : Rexulti

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 04, 2024

                          Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : H. Lundbeck AS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder.

                          Product Name : Rexulti

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 04, 2024

                          Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : H. Lundbeck AS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).

                          Product Name : Rexulti

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 25, 2024

                          Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : H. Lundbeck AS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Anagnostou, Evdokia, M.D.

                          Country arrow
                          EPSC
                          Not Confirmed

                          Anagnostou, Evdokia, M.D.

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Neurology

                          Study Phase : Phase II

                          Sponsor : Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 13, 2023

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Azrieli Foundation | Canadian Institutes of Health Research | Ontario Brain Institute | Holland Bloorview Kids Rehabilitation Hospital | McMaster University | Western University | Queen's University | University of Alberta | Alberta Health services | CHU

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).

                          Product Name : Rexulti

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 09, 2023

                          Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : H. Lundbeck AS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Sertraline hydrochloride potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). It is indicated for the treatment of MDD, PTSD, PMDD, panic disorder, and social anxiety disorder.

                          Product Name : Sertraline Hydrochloride-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 08, 2021

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          October 01, 2020

                          Lead Product(s) : Ketamine Hydrochloride,Sertraline Hydrochloride,Venlafaxine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Shanghai Mental Health Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Shanghai Mental Health Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 07, 2020

                          Lead Product(s) : Sertraline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank